A Phase 1, Open-label, 2-Part Study to Evaluate the Bioequivalence of the Duvelisib Marker-Image Formulation to the Duvelisib Clinical-Trial Formulation and to Assess the Effect of Food on the Pharmacokinetics of IP Duvelisib in Healthy Adult Subjects

Trial Profile

A Phase 1, Open-label, 2-Part Study to Evaluate the Bioequivalence of the Duvelisib Marker-Image Formulation to the Duvelisib Clinical-Trial Formulation and to Assess the Effect of Food on the Pharmacokinetics of IP Duvelisib in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Duvelisib (Primary)
  • Indications Allergic asthma; Chronic lymphocytic leukaemia; Follicular lymphoma; Haematological malignancies; Non-Hodgkin's lymphoma; Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors Infinity Pharmaceuticals; Verastem
  • Most Recent Events

    • 13 Oct 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 28 Aug 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 12 May 2015 Planned number of patients changed from 80 to 104 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top